Plasma levels of factor XIIa and factor VIIa are increased but not related in primary hyperlipidaemia

Blood Coagulation and Fibrinolysis

Volumn 12, Issue 3, 2001, Pages 187-192

  Cardigan, R A ^a,c   Crook, M ^b   Mackie, I J ^a   Machin, S J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

Cholesterol; Coagulation; Factor VIIa; Factor XIIa; Lipoprotein; Triglyceride

Indexed keywords

BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 7A; BLOOD GROUP ANTIGEN; CHOLESTEROL; LIPOPROTEIN; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPOLYSIS; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; THROMBIN TIME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035006058     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200104000-00004     Document Type: Article

References (38)

1. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men
2. Haemostatic function and ischaemic heart disease. Principal results of the Northwick Park Heart Study
3. Prospective study of hemostatic factors and incidence of coronary heart disease: The atherosclerosis risk in communities (ARIC) study
4. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease
5. Factor VII-deficient substrate plasmas depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: An international study
6. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease
7. The activation of factor VII in citrated plasma by charged long-chain fatty acids at the interface of large triglyceride-rich lipoproteins
8. Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition
9. The association of factor FVIIa, factor XIIa and β2-glycoprotein-1 with triglyceride-rich lipoproteins in normolipidaemic subjects
10. Activation of factor VII during alimentary lipaemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency but not in patients with factor IX deficiency
11. Plasma factor VII, triglyceride concentration and fibrin degradation products in primary hyperlipidaemia: A clinical and laboratory study
12. Assay of factor VII activity by two techniques: Evidence for increased conversion of FVII to αFVIIa in hyperlipidaemia, with possible implications for ischaemic heart disease
13. Coagulation factor VII and plasma triglycerides: Decreased catabolism as a possible mechanism of FVII hyperactivity
14. The prothrombin activation peptide regulates synthesis of the vitamin K-dependent proteins in the rabbit
15. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation
16. Increased activity of vitamin-K dependent clotting factors in human hyperlipoproteinaemia - Association with cholesterol and triglyceride levels
17. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors
18. Levels of activated FXII in survivors of myocardial infarction - Association with circulating risk factors and extent of coronary artery disease
19. Interrelationship of plasma triglyceride and coagulant factor VII levels in normotriglyceridaemic hypercholesterolaemia
20. Activation of the contact system of coagulation does not contribute to the haemostatic imbalance in hypertriglyceridaemia
21. Very low activated factor VII and reduced FVII antigen in familial abetalipoproteinaemia
22. Levels of factor VIIc associated with decreased TFPI and increased plasminogen activator in dyslipidaemias
23. Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidaemic patients
24. Risk of coronary heart disease and activation of factor XII in middle-aged men
25. FXII (46C-T) polymorphism and in vivo generation of FXII activity - Gene frequencies and relationships in patients with coronary artery disease
26. Activation of factor VII by Hageman factor fragments
27. A monoclonal antibody raised against human beta-factor XIIa which also recognizes alpha-factor XIIa but not factor XII or complexes of factor XIIa with C1 esterase inhibitor
28. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin
29. Contact activation: A revision
30. Simvastatin in non-insulin-dependent diabetes mellitus: Effect on serum lipids, lipoproteins and haemostatic measures
31. Pravastatin therapy in hyperlipidaemia: Effects on thrombus formation and the systemic hemostatic profile
32. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin
33. Effects of gemfibribrozil on lipids and haemostasis after myocardial infarction
34. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia
35. Hypertriglyceridaemia and hypercoagulability
36. Gemfibrozil reduces plasma prothrombin F1 + 2 concentration, a marker of coagulability in patients with coronary heart disease
37. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia without influencing fibrinogen, fibrin gel structure or coagulation factor VII
38. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipaemia in patients with combined hyperlipidaemia